Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2022-11-28 Regulatory Filings
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE IN SAN FRANCISCO
Regulatory Filings Classification · 91% confidence The document is a press release announcing that Medesis Pharma is presenting a scientific poster at the Clinical Trials on Alzheimer's Disease (CTAD) conference. It details the Phase II trial for NanoLithium® AD and mentions the presentation of the poster design. While it discusses clinical trial progress, the primary purpose of this specific document is to announce participation in a conference and the presentation of research findings, rather than being the full scientific report (AR), a general earnings release (ER), or a detailed investor presentation (IP). Since it is an announcement related to scientific/clinical progress and presentation materials, it most closely aligns with a general regulatory or informational announcement. Given the options, and since it is not a formal regulatory filing like 10-K or a specific financial report, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, although 'Investor Presentation' (IP) is a close second if the poster itself were attached or the focus was purely strategic. However, the text is a press release about a presentation, making RNS the most appropriate fallback for non-standard announcements.
2022-11-28 English
MEDESIS PHARMA PRÉSENTE UN POSTER SCIENTIFIQUE À LA CONFÉRENCE CLINICAL TRIALS ON ALZHEIMER'S DISEASE DE SAN FRANCISCO
Regulatory Filings Classification · 94% confidence The document is a press release announcing that MEDESIS PHARMA is presenting a scientific poster at the Clinical Trials on Alzheimer's Disease (CTAD) conference. It details the ongoing Phase II clinical trial for their drug candidate NanoLithium® AD, including enrollment status and expected results timelines. This type of announcement, focusing on scientific presentation, clinical trial updates, and participation in a specific medical conference, does not fit neatly into the standard financial filing categories (10-K, ER, IR, etc.). It is a general corporate update related to R&D progress. Given the options, the most appropriate fallback category for a specific, non-standard corporate announcement that isn't a formal financial report, management change, or dividend notice is 'Regulatory Filings' (RNS), as it serves as a general regulatory/corporate disclosure mechanism when a more specific code is unavailable. The document length is short (3782 chars) and it is not announcing the publication of a major report, thus RPA is not appropriate.
2022-11-28 French
MEDESIS PHARMA ANNOUNCES THE CONSTITUTION OF A PERMANENT SCIENTIFIC ADVISORY BOARD OF EXPERTS IN NEURODEGENERATIVE DISEASES
Board/Management Information Classification · 95% confidence The document is a press release announcing the constitution of a Permanent Scientific Advisory Board composed of experts in neurodegenerative diseases to support the company's research and clinical programs. This announcement concerns the structure and guidance for management/scientific strategy, specifically related to the Board of Directors' advisory functions. This aligns best with the 'Board/Management Information' category, as it details the formation of a key advisory body supporting the Board and management strategy, rather than being a formal financial report (10-K, IR, ER) or a specific legal/insider filing (DIRS, LTR, DVA).
2022-11-21 English
MEDESIS PHARMA ANNONCE LA CRÉATION D’UN CONSEIL SCIENTIFIQUE PERMANENT D’EXPERTS EN MALADIES NEURODEGENERATIVES
Board/Management Information Classification · 98% confidence The document is titled as an announcement ("ANNONCE LA CRÉATION") and is explicitly labeled as a "COMMUNIQUÉ DE PRESSE" (Press Release) at the end. It details the creation of a Permanent Scientific Advisory Board composed of renowned experts to advise the company (Medesis Pharma) on its R&D strategy for neurodegenerative diseases. This type of announcement, focusing on management/advisory structure changes and expert appointments, aligns best with the Board/Management Information category (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a presentation (IP).
2022-11-21 French
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2022
Report Publication Announcement Classification · 95% confidence The document is a press release from Medesis Pharma titled 'ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2022'. While it contains summary financial tables for the first half of 2022, the document explicitly states at the end: 'Le Rapport Financier Semestriel 2022 est mis à disposition du public et déposé auprès de l'Autorité des Marchés Financiers ce jour.' This confirms that the document itself is a press release announcing the availability of the actual financial report, rather than the full report itself. According to the 'MENU VS MEAL' rule, this is classified as a Report Publication Announcement (RPA). H2 2022
2022-10-25 French
MEDESIS PHARMA : RAPPORT FINANCIER SEMESTRIEL 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport Financier Semestriel 2022' (Semi-annual Financial Report 2022) and contains detailed financial statements, including a balance sheet (Bilan Actif/Passif) and income statement (Etats de gestion) for the period from 01/01/2022 to 30/06/2022. It provides substantive financial data rather than just an announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. H1 2022
2022-10-25 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.